Satellos Bioscience (NASDAQ: MSLE) has secured Fast Track designation from the U.S. Food and Drug Administration (FDA) for its drug SAT-3247, aimed at treating Duchenne muscular dystrophy (DMD).
This designation is intended to speed up the development and review process for drugs that address serious conditions with unmet medical needs.
SAT-3247 has already been recognized with Orphan Drug and Rare Pediatric Disease designations, underscoring its potential impact on DMD treatment.
The company is actively progressing SAT-3247 through Phase 2 clinical trials, known as BASECAMP and TRAILHEAD, which are being conducted on both children and adults affected by Duchenne.
Frank Gleeson, co-founder and chief executive officer of Satellos, commented, “Fast Track designation represents an important validation of SAT-3247 and our commitment to transforming the treatment landscape for Duchenne.”
